Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Trial Profile

Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Simeprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms SATURN
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 24 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 08 Apr 2015 Results will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL), as per Janssen Sciences media release.
    • 08 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov. record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top